deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02595398

Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis (PEACHTREE)

A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis

Sponsor: Clearside Biomedical, Inc.

Updated 14 times since 2017 Last updated: May 4, 2021 Started: Nov 17, 2015 Primary completion: Jan 18, 2018 Completion: Jan 18, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02595398, this PHASE3 trial focuses on Panuveitis and Uveitis and remains completed. Sponsored by Clearside Biomedical, Inc., it has been updated 14 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Aug 2017 · 4 months · monthly snapshot~Aug 2017 – ~Apr 2018 · 8 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jan 2021 · 27 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Jul 2024 · 37 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

14 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jun 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. May 2021 — Jun 2021 [monthly]

    Completed PHASE3

Show 9 earlier versions
  1. Apr 2021 — May 2021 [monthly]

    Completed PHASE3

  2. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE3

  3. Oct 2018 — Jan 2021 [monthly]

    Completed PHASE3

  4. Jun 2018 — Oct 2018 [monthly]

    Completed PHASE3

  5. Apr 2018 — Jun 2018 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  6. Aug 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  7. Apr 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  8. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Clearside Biomedical, Inc.
Data source: Clearside Biomedical, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .